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Abstract
Background: Cryptococcal meningitis (CM) is a severe AIDS-defining illness with 90-day case mortality as high as
70% in sub-Saharan Africa, despite treatment. It is the leading cause of death in HIV patients in Asia and Africa.
No major advance has been made in the treatment of CM since the 1970s. The mainstays of induction therapy are
amphotericin B and flucytosine, but these are often poorly available where the disease burden is highest. Adjunctive
treatments, such as dexamethasone, have had dramatic effects on mortality in other neurologic infections, but are
untested in CM. Given the high death rates in patients receiving current optimal treatment, and the lack of new agents
on the horizon, adjuvant treatments, which offer the potential to reduce mortality in CM, should be tested.
The principal research question posed by this study is as follows: does adding dexamethasone to standard antifungal
therapy for CM reduce mortality? Dexamethasone is a cheap, readily available, and practicable intervention.
Method: A double-blind placebo-controlled trial with parallel arms in which patients are randomised to receive either
dexamethasone or placebo, in addition to local standard of care. The study recruits patients in both Asia and Africa to
ensure the relevance of its results to the populations in which the disease burden is highest. The 10-week mortality risk
in the control group is expected to be between 30% and 50%, depending on location, and the target hazard ratio of
0.7 corresponds to absolute risk reductions in mortality from 30% to 22%, or from 50% to 38%. Assuming an overall
10-week mortality of at least 30% in our study population, recruitment of 824 patients will be sufficient to observe the
expected number of deaths. Allowing for some loss to follow-up, the total sample size for this study is 880 patients. To
generate robust evidence across both continents, we aim to recruit roughly similar numbers of patients from each
continent. The primary end point is 10-week mortality. Ethical approval has been obtained from Oxford University’s
Tropical Research Ethics Committee (OxTREC), and as locally mandated at each site.
Trial registration: International Standard Randomised Controlled Trial Number: ISRCTN59144167 26-July-2012
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Background and rationale
Background
Cryptococcal meningitis (CM) is estimated to cause 625,000
deaths every year, most occurring within 3 months of diag-
nosis [1]. It is the leading cause of death in HIV patients in
Asia and Africa, affecting 3.2% of the HIV-infected popula-
tion per year [1]. The incidence in these regions is the high-
est in the world; in Africa, more deaths are estimated to be
due to CM than to tuberculosis [1]. The 90-day case-fatality
rate is up to 55% in Asia and 70% in Africa [1].
Despite improvements in access to HIV care, the WHO
estimates that HIV/AIDS will be the leading cause of dis-
ease in middle- and low-income countries by 2015, and
models suggest that, even if 80% access to HIV treatment
is achieved by 2012, there will be 6.5 million AIDS deaths
p.a. by 2030 [2]. Thus, CM is likely to remain a significant
health burden for the foreseeable future.
No major advance has occurred in the treatment of
cryptococcal meningitis since the 1970s. The mainstays of
induction therapy are drugs that are more than 50 years
old (amphotericin B and flucytosine), although these are
often poorly available where the disease burden is highest.
Although amphotericin therapy is undoubtedly superior to
fluconazole monotherapy, amphotericin combination ther-
apy has only recently been shown to reduce mortality
when compared with amphotericin monotherapy. Whereas
effective antifungal therapy is the key, adjunctive treat-
ments, which have been seen to have dramatic effects on
mortality in other neurologic infections, are untested in
cryptococcal meningitis. Given the high death rates in pa-
tients receiving current optimal treatment, and the paucity
of new agents on the horizon, adjuvant treatments offer
the greatest potential to reduce mortality in CM.
This study aims to reduce the death rate from CM. The
principal research question is as follows: does adding
dexamethasone to standard antifungal therapy for CM re-
duce mortality? In this double-blind placebo-controlled
trial (DBRCT) patients will be randomised to receive either
dexamethasone or placebo. Dexamethasone is a cheap,
readily available, and practicable intervention.
This multicentre study recruits patients in both Asia
and Africa to ensure the relevance of the study results in
the populations in which the disease burden is highest.
Treatment of CM
Successful treatment of CM depends on effective antifun-
gal therapy and successful management of complications,
notably increased intracranial pressure (see Appendix 3).
Antifungal treatment schedules for cryptococcal meningi-
tis are not globally uniform but are affected by drug avail-
ability, costs, and human resources. The Infectious
Diseases Society of America convenes an international
panel to draw up treatment guidelines, most recently pub-
lished in 2010, and the WHO currently has guidelines in
development that will be specifically aimed at manage-
ment in resource-poor countries. These conform closely
to the IDSA guidelines. Treatment generally consists of a
period of induction therapy by using high-dose or combin-
ation antifungal therapy (usually for 2 weeks), followed by
a period of consolidation therapy of 8 weeks with flucona-
zole. After this time, provided that the patient has responded
to treatment, secondary prophylaxis using lower-dose flucon-
azole is given to prevent disease relapse. It is generally con-
sidered safe to stop secondary prophylaxis if ARV therapy
has resulted in suppression of the plasma viral load and im-
mune reconstitution with recovery of the CD4 cell count to
>100 cells/μl has lasted for at least 6 months).
Consistent with the local practices and the WHO and
IDSA guidelines, in this study, patients will receive anti-
fungal therapy consisting of amphotericin B (1 mg/kg/
day) combined with fluconazole, 800 mg/day for 2 weeks,
followed by fluconazole 800 mg/day for a further 8 weeks
before switching to secondary prophylaxis [3,4].
Rationale for adjuvant treatment with dexamethasone
Several mechanisms exist through which dexamethasone
may modify disease outcome in cryptococcal meningitis.
Current IDSA guidelines suggest that corticosteroids may
be beneficial in cryptococcal meningitis in patients who
have cryptococcomas with mass effect, acute respiratory
distress syndrome, or IRIS [4]. However, corticosteroids
have never been tested in a randomised controlled trial.
Of note, 150 of 381 patients in the ACTG trial of combin-
ation antifungal therapy in cryptococcal meningitis re-
ceived steroids during the study. The Graybill (2000) post
hoc analysis of these patients has some serious limitations
(1997) [5,6]. Steroids were prescribed at the discretion of
the attending physician, and the reasons for prescription
are unclear. The Graybill analysis was limited to just 41 of
the 150 steroid recipients, and did not report their impact
on mortality. Clinical success (defined as stabilisation or
improvement at 2 weeks) was lower in the 41 steroid re-
cipients analysed (66% versus 86%). Apparently worse
mycologic outcomes in these 41 patients are impossible to
interpret, because no adjustments were made for the anti-
fungal therapy received, fungal load, or clinical severity at
baseline, all of which are known to be important outcome
predictors [7,8]. The exclusion from the analysis of the
vast majority of patients who received steroids means that
it is impossible to draw robust conclusions about their ef-
fect and underlines the need for a trial.
In contrast with the article by Graybill, a study in
HIV-uninfected patients with C. gattii meningitis found
a 10-fold reduction in blindness in those who received
steroids [9]. Moreover, in tuberculous meningitis (TBM),
a disease that shares pathophysiologic features with CM,
dexamethasone has been shown to improve outcome
(RR of death, 0.69; 95% CI, 0.52 to 0.92; P =0.01) [10]. In
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this RCT, conducted in Vietnam, 545 patients were re-
cruited, of whom 98 were HIV infected. In addition to
the reduced risk of death, fewer adverse events were
found in patients receiving dexamethasone [10].
Potential mechanisms of action dexamethasone in CM
Antiinflammatory action
Cryptococcal meningitis is a chronic granulomatous men-
ingitis, with foci of inflammation in the basilar meninges,
cerebral mass lesions, and a lymphocytic cerebrospinal
fluid (CSF). The basilar meningitis leads to impairment of
resorption of CSF, and this, along with physical blockage
of CSF drainage by yeast cells and conglomerations of cap-
sule, is believed to contribute to the increased intracranial
pressure seen in the disease [11]. The immune response in
the mouse model mimics that seen in AIDS patients [12].
The effect of antiinflammatory agents has been tested in
this model. Reduction of inflammation prolongs survival
in mice infected with a lethal dose of C. neoformans [13].
Dexamethasone increases median survival from 19 to
26 days (P <0.05), a benefit preserved when dexametha-
sone is combined with amphotericin B [14]. Dexametha-
sone does not interfere with the pharmacologic properties
of amphotericin or fluconazole [14,15]. Moderation of the
inflammatory response is postulated to be through micro-
glial cells, a key in the immune response to CM [16].
Reduction of cerebral oedema and brain swelling
Cerebral oedema is a key feature of CM, and cryptococcal
capsule has been shown directly to induce cerebral
oedema [17]. Vascular endothelial growth factor (VEGF) is
a potent inducer of vascular permeability and angiogen-
esis, which has been implicated in the pathogenesis of
brain oedema [18,19]. Elevated levels are seen in both the
CSF and blood of HIV patients with cryptococcal menin-
gitis, and cryptococcal capsule has been shown to induce
VEGF production by monocytes, neutrophils, and periph-
eral blood mononuclear cells in a dose-dependent manner
[18,20]. In vitro, this induction is significantly downregu-
lated by dexamethasone [18]. Downregulation occurs at a
range of concentrations consistent with those achieved in
human dosing. A rat model of brain oedema suggests that
the effect of steroids on oedema is mediated through the
inhibition of VEGF [21]. Corticosteroids reduce vascular
permeability and limit oedema, and inhibition of VEGF
may explain the beneficial effect of steroid therapy in
TBM [10,22].
Reduction of intracranial pressure
Increased intracranial pressure (ICP) is frequent in CM
and is an important cause of mortality [5]. Dexamethasone
reduces increased ICP in models of other brain infections
[23-25]. The mechanisms are not clear, but through attenu-
ation of inflammation, cerebral oedema, and restoration of
the blood/brain barrier, it is plausible that dexamethasone
may reduce increased ICP in CM.
Modification of cerebral vasculitis
Cerebral vasculitis, frequently described in infections, is a
recognised feature of CM [26-29]. The pathophysiology
of neurologic vasculitis is relatively well understood: the
neurologic features arise principally through ischaemia
and infarction secondary to inflammation [30]. In infec-
tions, the vascular insult may be mediated through any or
all of vascular wall invasion, immune complexes, or cryo-
globulins. Of these, both endothelial invasion and immune
complex disease are described in cryptococcosis [31,32].
Steroids are an important therapeutic option in primary
cerebral vasculitides, and their beneficial effect in TBM
may be through an antivasculitic action [30]. Attenuation
of the vasculitis seen in CM may improve outcome.
Potential harms of dexamethasone
Reported side effects of dexamethasone are well described
and similar to those of other corticosteroids. Side effects
include dysglycaemia, changes in mood, Cushing-like
syndrome, gastrointestinal bleeding, immunosuppression,
hypertension, and secondary hypoadrenalism. Side effects
are more likely with higher doses (dexamethasone ≥16 mg/
kg/day) and longer courses of treatment [33]. Dexametha-
sone is frequently prescribed for patients with intracranial
pathology, including infectious diseases, and in addition,
data on adverse events are available from large RCTs of
dexamethasone that have been completed in tuberculous
meningitis (TBM) and acute bacterial meningitis (BM)
[10,34-36]. In the BM trials, the duration of steroid therapy
was 4 days, and in TBM, 6 to 8 weeks. In all these trials, ad-
verse events, including potentially life-threatening adverse
events such as gastrointestinal bleeding, were rare and were
no more common in patients receiving dexamethasone
compared with placebo.
In this study, patients will receive dexamethasone
0.3 mg/kg/day, reducing weekly over 6 weeks. This is
the lower dose that was used in the TBM trial for pa-
tients with Grade I disease [10]. The risk and severity of
any adverse events must be considered in the context of
the high mortality seen in cryptococcal disease. Notably,
dexamethasone has no mineralocorticoid effect and is
not associated with hypokalaemia [37].
Immunosuppression
Corticosteroids are immunosuppressive. It is possible that
they may slow yeast clearance from CSF, and increase the
risk of other infections. However, animal studies suggest
that dexamethasone improves yeast clearance from CSF
[14]. Even if the rate of yeast clearance is reduced, this
may not be detrimental. In this study, we will measure the
rate of clearance of yeast from CSF (see Appendix 1).
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Patients with CM are profoundly immunosuppressed: the
median CD4 count in Vietnamese patients is 16 cells/μl
(which compares with a median CD4 count of 42 in
Vietnamese HIV patients with tuberculous meningitis)
[38]. Given this, whether dexamethasone will significantly
increase the risk of other opportunistic infections (OIs) is
not clear. The incidence of other OIs is a secondary end
point of the study. Patients in the study will receive
chemoprophylaxis against Pneumocystis jirovecii and other
opportunistic infections, in line with national guidelines.
Patients will be screened for TB at study entry as part of
normal care.
Secondary hypoadrenalism
Adrenal suppression is a recognised risk in patients re-
ceiving corticosteroid therapy for prolonged periods or
in higher doses. With a treatment course of the length
in this study, adrenal suppression will be short lived and
is prevented through the gradual reduction in dose, as
stipulated in the protocol. Patients must be provided
with an information card detailing the importance of
taking the steroids as per the study protocol, and so that
other doctors who attend them will be aware of their
prescription. Steroid information cards must be provided
in the local language. Steroids will be administered in a
reducing dose according to best medical practice.
Hyperglycaemia
Reversible hyperglycaemia is a recognised side effect of
corticosteroids. Hyperglycaemia is uncommon in patients
receiving dexamethasone in this dose, with elevated fast-
ing glucose occurring in fewer than 1% of patients and
equally frequently amongst TBM patients receiving active
drug or placebo [10]. A review of the adverse effects of
corticosteroids in severe sepsis found an increased abso-
lute risk of hyperglycaemia of 5.6% [39].
Cushing-like syndrome
A Cushing- type syndrome can develop in people receiv-
ing prolonged steroid therapy, with weight gain, redistri-
bution of body fat, and acne. However, in the dose and
duration given in this study, development of Cushing
syndrome is unlikely. Moreover, it is reversible on treat-
ment cessation.
Gastrointestinal bleeding
Data from TBM, bacterial meningitis, and sepsis suggest
that corticosteroids do not increase the risk of gastro-
intestinal bleeding when used in these dosages and dura-
tions [10,35,36,39].
Hypertension, salt retention, and hypokalaemia
These effects of corticosteroids are due to their min-
eralocorticoid action. Because dexamethasone belongs to
the glucocorticoid group, the risk of these side effects is
negligible.
Overview of the trial
A multicentre double-blind randomised placebo-controlled
trial of adjunctive treatment with dexamethasone in adults
with HIV-associated cryptococcal meningitis
Study aim: To reduce mortality from cryptococcal men-
ingitis in HIV-infected adult patients
Intervention: Dexamethasone in a reducing dose over
the first 6 weeks of treatment
Randomisation: 1:1 study-intervention versus placebo,
by using variably sized blocks and stratified by site
Primary end point: Survival during the first 10 weeks
after randomisation
Antifungal therapy: Amphotericin B, 1 mg/kg/day +
fluconazole 800 mg/day for 2 weeks, followed by flucon-
azole, 800 mg/day for 8 weeks, followed by secondary
prophylaxis with fluconazole, 200 mg/day
Secondary end points: Survival during 6 months after
randomisation, disability, rates of fungal clearance, rates of
visual impairment, rates of IRIS, rates of new AIDS-
defining illnesses, frequency of grade 3, grade 4, or serious
adverse events, rates of increased intracranial pressure,
time to new neurologic events, health economics analysis.
Sample size: 880 patients (roughly equal numbers from
Asia and Africa)
Participating countries: Uganda, Malawi, Vietnam,
Thailand, Indonesia, Laos
Study sponsor: Oxford University
Study funding: The UK Department for International
Development, The Wellcome Trust (UK), and the Medical
Research Council (UK) Joint Global Health Trials Scheme
Study duration (recruitment and follow-up): 3 years
(Figures 1 and 2).
Study aims
Primary aim
To investigate the effect of dexamethasone adjunctive
therapy on 10-week survival in HIV-infected adult patients
with cryptococcal meningitis
Secondary aims
The secondary aims are to determine the effect of
adjuvant treatment with dexamethasone on survival at
6 months, disability at 10 weeks and 6 months, the rate of
sterilisation of cerebrospinal fluid (CSF), the frequency of
grades 3, 4, and serious adverse events, the incidence
of IRIS, the incidence of other opportunistic infections, re-
peated treatment for cryptococcal meningitis, the presence
of visual deficit at 10 weeks, and health economics. In
addition, the effect of steroids on survival by continent will
be assessed.
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End points
Primary end point
The primary outcome is overall survival until 10 weeks
after randomisation.
Secondary end points
Survival until 6 months after randomisation
Relapse occurs in cryptococcal meningitis. Most cases
occur within 6 months of diagnosis. We will collect sur-
vival data at 6 months (alive versus date of death) to en-
sure that any survival benefit at 10 weeks is sustained at
6 months, and not negated by, for example, a higher re-
lapse rate in patients receiving steroids.
Disability at 10 weeks and 6 months
Neurologic disability will be assessed by using the modi-
fied Rankin score and the Two Simple Questions and clas-
sified as good, intermediate, severe disability, or death, as
previously described (Table 1) [10].
Disability is an expected consequence of cryptococcal
meningitis, including blindness, deafness, and other focal
neurological deficits. In addition to reduced death rate,
patients receiving dexamethasone may also have lesser
(or higher) rates of these disabilities. The Rankin score
and the Two Simple Questions are well-validated mea-
sures of the degree of disability in stroke survivors, and
have been used frequently to measure disability after
neurologic infections.
Figure 1 Trial flow diagram.
Day 1:
Study Entry Day 3 Day 7 Day 11 Day 14 Day 21 Day 28 Day 42 Day 70 Day 182
Take informed consent
Clinical Assessment**
FBC (Hb, WCC, plt) 1ml
Na, K, Urea, creat, glu 2ml # # #
CD4 / CD8 count 2ml
HIV anbody 2ml
Blood cultures 5ml
CSF Opening pressure If indicated If indicated If indicated
Lateral Flow Angen on CSF
CSF Gram stain, India Ink 0.5ml If indicated If indicated If indicated
CSF cell count, protein, glucose 1ml If indicated If indicated If indicated
CSF TB smear 6ml***
CSF Yeast Quant Count 1ml If indicated If indicated
Store C. neoformans isolate****
Store CSF supernatant and pellet If indicated If indicated If indicated
Sputum TB smear*****
Chest X-ray***
Store blood plasma 4.5ml
Store blood cell pellet
Approximate blood volume ml 16.5 2 3 2 3 3 3 2
Approximate CSF volume ml 8.5 2-5 2-5 2-5
Figure 2 Trial flow chart.
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Rate of CSF sterilisation during the first 2 weeks
It is conceivable that dexamethasone could slow the rate
of CSF sterilisation, although this is not seen in the ani-
mal model. In a subset of patients, we will measure the
repeated fungal burdens in CSF over the first 2 weeks of
treatment, model the rate of decline, and determine the
effect of dexamethasone on fungal clearance. We will
also determine whether the rate of CSF sterilisation is
predictive of mortality in both study arms, based on
joint modelling of longitudinal fungal counts and mor-
tality. Specifically, the longitudinal model will be a mixed
model with fixed effects for the intercept, time (that is,
the slope), and a treatment-time interaction and random
(bivariate normal) effects for the intercept and the slope.
The Cox survival model will have shared random effects
with the longitudinal model.
Adverse events
Comparison of the proportion of patients with any grade
3 or 4 adverse event and of serious adverse events between
treatment groups will form an important part of the study
analysis, to determine the safety of the intervention.
Rate of IRIS until 10 weeks
We will model the rate of IRIS over time with a cause-
specific hazards model, taking into account the competing
risk of prior death. CM-related IRIS will be defined as per
the recent proposed definition (see Appendix 2) [40].
Time to new AIDS-defining illnesses or death until 10 weeks
AIDS-defining illnesses will be defined as per the WHO
classification (see Table 2).
Visual deficit at 10 weeks
Retrospective data from HIV-uninfected patients with
meningitis due to Cryptococcus gattii suggest that ste-
roids may have a profound effect in reducing visual loss;
10% of Vietnamese HIV patients have visual impairment
at 10 weeks [41]. We will compare the incidence of
blindness and other visual deficits between treatment
groups. Visual deficit will be assessed by using a simple
6-point scale (see Table 3).
Time to new neurologic event or death until 10 weeks
A neurologic event is defined as a decrease in Glasgow
coma scale score by ≥2 points for ≥2 days from the highest
previously recorded Glasgow coma scale score (including
baseline) or the occurrence of any of the following adverse
events: cerebellar symptoms, coma, hemiplegia, paraple-
gia, seizures, cerebral herniation, new-onset blindness or
deafness, or cranial nerve palsy.
Longitudinal measurements of intracranial pressure during
the first 2 weeks
Intracranial pressure (ICP) will be measured at study entry,
days 3, 7, and 14, and if clinically indicated (depending on
local practice). The main outcomes are longitudinal ICP
measurements until day 14, and we will model the effect
of dexamethasone on ICP based on a joint model for lon-
gitudinal and survival data similar to the model described
for rate of CSF sterilization, above.
Clinical need and local practice will determine the fre-
quency of lumbar punctures after day 14 and clinician’s
diagnoses of increased ICP based on the presence of head-
ache, nausea, diurnal and postural variation, relief with
lumbar puncture, and presence of papilloedema will be
somewhat subjective.
Table 1 Outcome and disability grading: “two simple questions” and rankin score
The two simple questions
Does the patient require help from anybody for everyday activities?
(For example eating, drinking, washing, brushing teeth, going to the toilet.)
Yes/no Yes = Poor outcome
Has the illness left you with any other problems? Yes/no Yes = Intermediate outcome
No = Good outcome
The modified rankin scale
Grade Description
0 No symptoms
1 Minor symptoms not interfering with lifestyle
2 Symptoms that lead to some restriction in lifestyle, but do not interfere
with the patients’ ability to look after themselves
3 Symptoms that restrict lifestyle and prevent totally independent living
4 Symptoms that clearly prevent independent living, although the patient
does not need constant care and attention
5 Totally dependent, requiring constant help day and night
Grade 0: Good outcome, Grade 1 or 2: Intermediate outcome, Grade 3-5: poor outcome.
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Antifungal treatment intensification or retreatment for
cryptococcal meningitis in the 6 months after randomisation
Relapse occurs in patients with cryptococcal disease. All
patients will be receiving either treatment doses of anti-
fungal therapy or secondary prophylaxis doses during
the 6-month period of follow-up. Although all patients
will be encouraged to return to the study hospital in the
event of illness during the 6-month follow-up period, it
is possible that, because of their location, some patients
will undergo treatment elsewhere where diagnostic facil-
ities may be less developed. This episode may only be
identified at the 6-month follow-up period. For this rea-
son, a pragmatic definition of relapse will be used. This
is defined as either intensification of antifungal therapy
above that according to the study antifungal schedule, or
readmission for treatment of cryptococcal disease. The
main outcome measure will be the cause-specific hazard
of relapse, taking into account the competing risk of
death.
Health economics
If effective, the low cost of dexamethasone makes it
promising as a cost-effective intervention in low-income
settings. To assess this formally, a cost-effectiveness ana-
lysis will be conducted in collaboration with the Health
Economics Research Centre, University of Oxford. The
objective of the analysis will be to estimate the incre-
mental cost-effectiveness ratio (ICER), expressed as cost
per life year gained and cost per Quality Adjusted Life
Year (QALY) gained and per Disability Adjusted Life
Year (DALY) averted of dexamethasone treatment com-
pared with standard antifungal therapy for cryptococcal
meningitis (CM).
The analysis will collect information during the study on
resources used and direct and indirect costs, including
health care costs (treatments, medications, consultations,
initial and subsequent hospitalisations), and patient/family
incurred costs (out-of-pocket costs, employment). Health-
care resources used will be obtained primarily from trial
case record forms. Unit costs will be obtained in each coun-
try from participating centres and national sources. Infor-
mation on patient-employment status and costs will be
Table 2 WHO clinical staging for HIV/AIDS
Clinical stage 1 Asymptomatic
Persistent generalised lymphadenopathy (PGL)
Performance scale 1: asymptomatic, normal activity
Clinical stage 2 Weight loss, <10% of body weight
Minor mucocutaneous manifestations (seborrheic
dermatitis, prurigo, fungal nail infections, recurrent
oral ulcerations, angular cheilitis)
Herpes zoster, within the last 5 years
Recurrent upper respiratory tract infections (for
example, bacterial sinusitis)
And/or performance Scale 2: symptomatic, normal
activity.
Clinical stage 3 Weight loss, >10% of body weight
Unexplained chronic diarrhoea, >1 month
Unexplained prolonged fever (intermittent or
constant), >1 month
Oral candidiasis (thrush)
Oral hairy leukoplakia
Pulmonary tuberculosis, within the past year.
Severe bacterial infections (for example, pneumonia,
pyomyositis)
And/or Performance scale 3: bedridden, <50% of the
day during the last month
Clinical stage 4 HIV wasting syndrome, as defined by CDC1
Pneumocystis carinii pneumonia
Toxoplasmosis of the brain
Cryptosporidiosis with diarrhoea, >1 month
Cryptococcosis, extrapulmonary
Cytomegalovirus (CMV) disease of an organ other
than liver, spleen, or lymph nodes
Herpes simplex virus (HSV) infection, mucocutaneous
>1 month, or visceral of any duration
Progressive multifocal leukoencephalopathy (PML)
Any disseminated endemic mycosis (for example,
histoplasmosis, coccidioidomycosis)
Candidiasis of the oesophagus, trachea, bronchi, or lungs
Atypical mycobacteriosis, disseminated
Nontyphoid Salmonella septicaemia
Extrapulmonary tuberculosis
Lymphoma
Kaposi sarcoma (KS)
HIV encephalopathy, as defined by CDC2
And/or Performance scale 4: bedridden, >50% of the
day during the last month
(Note: Both definitive and presumptive diagnoses are acceptable).
1HIV wasting syndrome: weight loss of >10% of body weight, plus either
unexplained chronic diarrhoea (>1 month), or chronic weakness and unexplained
prolonged fever (>1 month).
2HIV encephalopathy: clinical finding of disabling cognitive and/or motor
dysfunction interfering with activities of daily living, progressing over weeks to
months, in the absence of a concurrent illness or condition other than HIV
infection that could explain the findings.
Table 3 Visual assessment
Visual assessment – record the best performance
Function Score
Normal 1
Blurred 2
Finger counting 3
Movement perception 4
Light perception 5
No light perception 6
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obtained from patients by a small number of questions ad-
ministered at recruitment and again at the final follow-up
(10-week) visit. The main measures of effectiveness will be
(a) life years gained (b) quality-adjusted life years gained
(QALYs), estimated by using the EQ-5D instrument in offi-
cial English, Vietnamese, and Thai languages in its three-
level version, and (c) disability-adjusted life years (DALYs)
averted, which measures both years of life lost because of
premature mortality and years lived with disability. Life
years gained will be based on the primary outcome measure
of survival at 10 weeks, extrapolated by using best estimates
of longer-term survival in each country for HIV-infected
adults. QALY and DALY estimates will adjust the life-year
estimates by taking into account secondary end points,
including blindness, deafness, and other neurologic disabil-
ities that are important sequelae of cryptococcal disease.
QALY adjustment will be done by using EQ-5D-3 L re-
sponses, and DALY adjustment by using clinical judgment
to align recorded morbidity with DALY states. The use of
both approaches will provide internal validity checks and
maximise opportunities to present relevant information to
decision makers.
As unit costs, absolute risks, life expectancy, and other
variables are likely to differ substantially across regions,
separate cost-effectiveness estimates will be produced for
Asia and Africa; however, a trial-wide estimate of effective-
ness will be applied unless clear evidence exists of hetero-
geneity in effect across regions. All estimates of costs,
outcomes, and cost-effectiveness will be reported with full
recognition of uncertainty, including cost-effectiveness ac-
ceptability curve and sensitivity analyses around key pa-
rameters, including unit costs, long-term life expectancy,
and disability adjustment.
The economic evaluation is concerned primarily with
estimation of cost and outcome differences and cost-
effectiveness rather than hypothesis testing, and a power cal-
culation for a ratio statistic is likely to be highly uncertain,
especially as the DALY/QALY measure (the denominator)
will itself be a composite of survival and quality/disability
adjustment. The proposed size of the study (880 patients)
should permit cost differences of 12% or greater to be reli-
ably detected by assuming a coefficient of variance of 60%.
Methods
Study design
A randomised, double-blind, placebo-controlled trial with
two parallel arms: dexamethasone versus placebo during
the first 6 weeks of treatment. This multicentre study will
recruit patients who offer informed consent across Asia
and Africa, in Malawi, Uganda, Laos, Thailand, Indonesia,
and Vietnam. The study is pragmatic, designed to main-
tain relevance through trialing adjuvant treatment with
dexamethasone in the context of the best standard of lo-
cally available care.
Dexamethasone-treatment dose
Dexamethasone will be given in a reducing dose accord-
ing to body weight (Table 4):
This dose is identical to the dose used in patients with
Grade 1 tuberculous meningitis and has been shown to
have a low rate of side effects [10]. Dexamethasone/
placebo will be administered intravenously, during the
period of intravenous antifungal treatment, and orally
once antifungal treatment is administered orally. Treat-
ment will be weight-dosed to the nearest half milligram.
With the exception of the first dose, which should be
given with the first dose of antifungal therapy, dexametha-
sone should be given in the morning.
Study population
All HIV-infected adult patients with a diagnosis of CM
presenting to the study centres will be eligible to enter
the study, subject to meeting the inclusion/exclusion cri-
teria and giving informed consent.
Trial location
The study will recruit patients at sites in Vietnam,
Indonesia, Thailand, Laos, Uganda, and Malawi.
Inclusion criteria
 Age ≥18 years
 HIV antibody positive
 Cryptococcal meningitis defined as a syndrome
consistent with CM and one or more of
○ positive CSF India ink (budding encapsulated
yeasts),
○ C. neoformans cultured from CSF or blood,
○ positive cryptococcal antigen Lateral Flow
Antigen Test (LFA) in CSF
Informed consent to participate given by patient or
acceptable representative
Exclusion criteria
 Pregnancy
Table 4 Dexamethasone-reducing regimen
Period Dexamethasone Dose Timing
Week 1 0.3 mg/kg iv Once daily
Week 2 0.2 mg/kg iv Once daily
Week 3 0.1 mg/kg po Once daily
Week 4 3.0 mg total/day po Once daily
Week 5 2.0 mg total/day po Once daily
Week 6 1.0 mg total/day po Once daily
Week 7 onwards Stops
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 Active gastrointestinal bleeding (defined as vomiting
blood or melena stool in the previous week)
 Currently receiving treatment for CM and having
received ≥1 week of anti-CM therapy
 Known allergy to dexamethasone
Current steroid use defined as
a) currently receiving the equivalent of prednisolone
40 mg/day or more
b) currently receiving steroid therapy (any dose) for
more than 3 weeks (except topical steroids, which
are permitted)
 Concurrent condition for which corticosteroids are
indicated because of proven benefit (such as severe
Pneumocystis pneumonia (pO2 < 70 mm Hg) or
tuberculous meningitis)
 Renal failure (defined as creatinine >3 × ULN,
despite adequate hydration)
Study procedures
Recruitment
The target population for study screening is any patient
known or suspected to have CM. To enter the study, pa-
tients must be confirmed to have CM according to the
definition in the inclusion criteria. Screening procedures
will adapt to the standard of care of each setting to en-
sure that study-related procedures are performed only
after informed consent has been obtained. According to
the clinical care of the treating hospital, patients sus-
pected of having CM will undergo
a) an IMMY lateral-flow cryptococcal antigen test
(LFA) on serum or plasma,
AND/OR
b) blood culture for Cryptococcus
AND/OR
c) a lumbar puncture with an IMMY lateral-flow
cryptococcal antigen test, and/or microscopic exam-
ination of CSF, and/or culture of CSF.
d) When the results of the IMMY lateral-flow test
(plasma, serum, or CSF), or CSF microscopy, or
blood or CSF culture are available, study staff may
consider whether the patient should be approached
regarding the study. Only patients 18 years or older
who are not known to be pregnant and who have
evidence of cryptococcal disease from one of the
specified tests will be approached.
A member of study staff will invite the patient to discuss
the details of the study. If the patient is judged by the staff
to be unfit or unable to give informed consent, an accept-
able representative will act on the patient’s behalf for the
following procedures. The study staff will give the patient/
representative a copy of the informed-consent form and
explain the details of the study, including the study pro-
cedures, risks and benefits, financial and confidentiality
considerations, treatment alternatives, and how to obtain
more information. The study staff will invite the patient/
representative to ask questions and will endeavour to en-
sure that she or he understands the information given.
The study staff will then ask the patient/representative to
consider study participation. Those who refuse consent
will be treated as per the best available standard care and
will not have any study-related procedures performed.
Those who consent to the study will sign and date two
copies of the informed-consent form. The study staff will
also sign and date the two copies.
If the patient/representative is illiterate, a witness who is
not a member of the study staff will be present during the
informed-consent discussion. The informed-consent form
will be read to the patient/representative in the presence
of the witness. If the patient/representative agrees to par-
ticipate, the form will be signed and dated by the witness.
Consenting patients will be screened for eligibility.
Screening
Only patients who are 18 years or older, who are not
known to be pregnant, and who have at least one of posi-
tive CSF or blood/serum LFA test, positive blood or CSF
culture, or positive CSF microscopy will be consented.
Consenting patients will undergo the following screening
procedures/tests. In the case of an unconscious patient, in-
formation will be obtained from a knowledgeable relative
or caregiver.
– Medical history will be taken, including: (a) signs
and symptoms consistent with cryptococcal
meningitis, (b) allergy to dexamethasone, and (c)
history of corticosteroid use and antifungal therapy.
– Patient will be checked for signs of active
gastrointestinal bleeding.
– All women of child-bearing age will have a urine or
blood pregnancy test.
– Creatinine level
– HIV status will be confirmed from clinical history or
testing as per standard of care.
– A lumbar puncture will be performed on all patients
to obtain CSF. CSF will be tested by: (a) India ink
stain or equivalent, (b) culture, and (c) lateral-flow
cryptococcal antigen test. Cultured isolates will be
stored for subsequent studies.
– If a lumbar puncture was done recently (within
48 hours) for clinical care, and volume of fresh CSF
remains available for these tests (stored according to
established SOPs), the lumbar puncture need not be
repeated.
– If the patient underwent a recent lumbar puncture,
an additional puncture will be performed (provided
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no contraindications exist) if any of the following
are true: (a) uncertainty exists regarding the
microbiologic diagnosis, (b) increased intracranial
pressure is suspected, (c) the previous puncture was
>2 days before, and no effective treatment has been
given, and (d) it is required for standard care. If
none of these is true or if the patient refuses further
lumbar puncture, the patients may be randomised
without additional lumbar puncture, provided they
are eligible for the study.
– If the lumbar puncture was not recent, it will be
repeated (provided no contraindications exist) to
confirm the diagnosis, and to determine CSF
pressure and fungal burden.
All lumbar punctures require verbal or written consent
according to local standard clinical practice. Failure to
consent according to local practice is a contraindication
to the procedure.
When all inclusion and exclusion criteria are verified,
eligible patients will be randomised to treatment.
Patients who are determined to be ineligible will be
withdrawn from the study, and the reason recorded. Pa-
tients withdrawn from the study will be treated accord-
ing to the best available standard care. Screening flow is
illustrated in Figure 3.
The number of patients who do meet inclusion/exclu-
sion criteria, but are not enrolled in the study will be
recorded.
Randomisation
Randomisation will be 1:1 to either dexamethasone or
identical placebo. Patients will be stratified by hospital of
enrolment. Enrolment logs specific to each site will be used
to assign patients to the next available sequential number.
The assigned number will correspond to a blinded, sealed,
treatment pack containing dexamethasone for injection
and dexamethasone tablets, or visually identical placebos.
Treatment packs will be prepared centrally by an un-
blinded study pharmacist and distributed to the sites in
batches, as required. Only central study pharmacists who
hold the master randomisation list will know the contents
of each pack. This list will be accessed only in the case of
emergency unblinding, authorised by an investigator or
designee, as per standard operating procedures. At each
site we will use block randomisation with variable block
lengths of size 4 (with probability 0.75) or 6 (with probabil-
ity 0.25), respectively. Stratification by site will minimise
the effect of any differences in patient or health care char-
acteristics by ensuring that nearly equal numbers of pa-
tients receive either of the two treatment arms at each site.
Drug appearance and administration schedules will be
identical to maintain blinding amongst the attending phy-
sicians and nurses.
Patient management
Initial evaluation
On admission, all patients will have a full clinical assess-
ment and examination.
Study-entry laboratory tests will be performed as per
the study schedule in section Treatment of CM.
A baseline chest radiograph will be performed. A CT
or MRI brain scan will be performed if evidence is found
of increased intracranial pressure or focal neurologic ab-
normalities according to local practice and resources.
Other treatment
Antifungal treatment
All patients will receive antifungal treatment consisting of
2 weeks of intravenous amphotericin B, 1 mg/kg/day, com-
bined with high-dose fluconazole (800 mg/day), followed by
fluconazole 800 mg/day for 8 weeks (10 weeks in total; see
Appendix 4 and Appendix 5). This is locally feasible and
consistent with recent guidelines [3,4]. After the 10-week
period of therapy, all patients, provided they have responded
to treatment, will receive long-term secondary prophylaxis
with fluconazole, 200 mg/day. Modification of antifungal
therapy will be made according to the patient’s needs and
the judgment of the attending physician. Any changes to an-
tifungal therapy will be recorded in the case-record form.
The cost of antifungal treatment (including secondary
prophylaxis until 6 months after randomisation) will be cov-
ered by existing local financial support or trial finances.
Antiretroviral therapy
All patients must to be referred to local HIV services as
soon as practicable, preferably while still admitted to
hospital, to ensure that they have access to locally avail-
able HIV services, including counselling and ARVs.
It is not clear when antiretroviral therapy should be
started in CM. Large studies are currently under way to
answer this question. Early initiation may offer faster im-
mune reconstitution benefiting survival, or may increase
the risk of IRIS and drug toxicities, adversely affecting
survival. In the absence of reliable data, most physicians
would recommend starting ARVs after 4 weeks of anti-
fungal treatment, provided the patient has made a good
response. The date that ARVs are started (or stopped) in
patients in the study will be recorded.
Opportunistic infection prophylaxis
Most patients will be profoundly immunosuppressed and
should receive prophylactic therapy against other opportun-
istic infections, such as daily trimethoprim-sulfamethoxazole,
in accordance with local guidelines and practices.
Hospital admission
Intravenous amphotericin B is administered for 14 days,
necessitating hospital admission during this period.
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Figure 3 Screening-study flow diagram.
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Clinical monitoring
Patients will have daily GCS and review, as per standard
care, until discharge from hospital. The decision to dis-
charge patients from the hospital is at the attending phy-
sician’s discretion and is based on the clinical status of
the patient. After discharge, patients will be seen weekly
until 4 weeks, at 6 weeks, and at 10 weeks. If the exact
visit day is not feasible, scheduled visits can occur at up
to 5 days after the stipulated time to account for week-
end and holidays (for example, the 4-week review should
occur on day 28 to 33 after randomisation, and week 10
visit on day 70 through 75). Patients will be monitored
closely for
 Death: the date of death and cause will be recorded
 New neurologic events (onset of new focal
neurologic signs or decrease in Glasgow coma scale
score of ≥2 points for ≥2 days, after >7 days clinical
stability or improvement after randomisation)
 Drug-related adverse events
 New or recurrent AIDS-defining illnesses (see
Table 5)
 Visual deficit (at week 10)
 IRIS
 Increased intracranial pressure (clinical or
measured)
Uniform management of patients and recording of
data will be ensured by the local study staff, who will do
clinical assessments daily while admitted and at follow-
up visits.
Disability and mortality at 6 months and evidence of
morbidity (including IRIS) since last seen (week 10) will be
collected with either a structured telephone interview or an
outpatient visit. Outpatient visits may occur in the patient’s
home when the patient cannot come to the hospital.
Laboratory monitoring
Inpatient laboratory monitoring will be as shown in the
study schedule (section Treatment of CM).
Other investigations may be performed as clinically in-
dicated. Data for the following will be recorded when
performed for routine clinical care:
 CSF, if neurologic deterioration (Gram stain and
routine culture, ZN stain and mycobacterial culture,
India ink stain, and fungal quantitative culture)
 Sputum, if symptomatic (routine culture, ZN stain)
 Urine culture, if urinary symptoms (urine culture)
 Stool examination, if prolonged diarrhoea
(microscopy, culture, and parasites)
 Blood cultures, if persistent fever
 Lymph node aspiration (routine and mycobacterial
cultures)
 Blood glucose will be measured when CSF is
examined or if hyperglycaemia is suspected
A window period of ±2 days outside of the scheduled
laboratory tests will apply to all tests that are not base-
line inclusion/exclusion criteria.
Imaging
A chest radiograph must be performed on study entry if
it has not been done at the time of diagnosis. The result
will be recorded in the CRF. Brain imaging is not man-
dated by the study. The decision to perform brain im-
aging will be according to local practice. Results of brain
imaging, when available, will be recorded.
Management of adverse events
Possible side effects of dexamethsone were described
earlier.
Given the experience from tuberculous meningitis,
gastrointestinal haemorrhage is extremely unlikely (it
occurred more frequently in placebo recipients than in
patients receiving dexamethasone in the large randomised
controlled trial from Vietnam). Gastrointestinal hae-
morrhage will be treated as per local practices, with car-
diovascular support and proton pump inhibitors or H2
antagonists. Hyperglycaemia will be managed with insulin.
Stopping study drug and unblinding rules
The purpose of the randomised, double-blind design of
the trial is to protect the results from the potential influ-
ence of study staff or patient bias about which treatment
is the most effective.
Occasionally it can be necessary to STOP the study
intervention (placebo or dexamethasone) or to UNBLIND
the patient’s treatment allocation.
Note:
 STOPPING study drug does not necessitate
UNBLINDING the treatment allocation.
UNBLINDING treatment is not necessarily an
indication to STOP treatment.
 STOPPING or UNBLINDING a patient’s treatment
does not mean that they have withdrawn from the
study. Patients continue in the study and follow the
protocol schedule for visits and investigations until
its conclusion at 6 months of follow-up.
Stopping study drug
Because of the risk of corticosteroid-induced adrenal sup-
pression, the study drug must be stopped in a carefully
controlled manner. Few good-quality data are available to
enable prediction of the degree of adrenal suppression that
occurs with corticosteroid therapy. Therefore, conven-
tional rules for management of corticosteroid withdrawal
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Table 5 Presumptive and definitive criteria for AIDS-defining events
Presumptive criteria Definitive criteria
Constitutional disease
HIV wasting syndrome Unexplained involuntary weight loss >10% from baseline PLUS
persistent diarrhoea with ≥2 liquid stools/day for >1 month
OR chronic weakness OR persistent fever >1 month. Should
exclude other causes such as cancer, TB, MAC,
cryptosporidiosis or other specific enteritis
Infections
Aspergillosis, other invasive CXR abnormality compatible with aspergillosis PLUS invasive
mycelia consistent with Aspergillus on lung biopsy or positive
culture of lung tissue or positive culture of sputum
CXR abnormality compatible with aspergillosis PLUS
invasive mycelia consistent with Aspergillus on lung
biopsy PLUS positive culture of lung tissue or positive
culture of sputum
Bartonellosis Clinical evidence of bacillary angiomatosis or bacillary peliosis
PLUS positive silver stain for bacilli from skin lesion or affected
organ
Clinical evidence of bacillary angiomatosis or bacillary
peliosis PLUS positive culture or PCR for Bartonella
quintana or Bartonella henselae
Candidiasis of bronchi,
trachea or lungs
None Macroscopic appearance at bronchoscopy or histology
or cytology (not culture)
Candidiasis, oesophageal Recent onset retrosternal pain on swallowing PLUS clinical
diagnosis or oral candidiasis by cytology (not culture) PLUS
clinical response to treatment
Macroscopic appearance at endoscopy or histology or
cytology (not culture)
Coccidiodomycosis,
disseminated or
extrapulmonary
None Histology or cytology, culture or antigen detection from
affected tissue
Cryptococcosis,
meningitis or pulmonary
None Histology or cytology/microscopy, culture or antigen
detection from affected tissue
Cryptosporidiosis None Persistent diarrhoea >1 month, histology or microscopy
CMV retinitis Typical appearance on fundoscopy of discrete patches of
retinal whitening, associated with vasculitis, haemorrhage, and
necrosis, confirmed by ophthalmologist
None
CMV end-organ disease None Compatible symptoms plus histology or detection of
antigen from affected tissue
Infections Presumptive criteria Definitive criteria
CMV radiculomyelitis Leg weakness and decreased reflexes or syndrome consistent
with cord lesion presenting subacutely over days to weeks. CT/
MRI shows no mass lesion. CSF shows >5 WBC with >50%
polymorphs and positive CMV PCR, antigen or culture
None
CMV
meningoencephalitis
Rapid (days to <4 weeks) syndrome with progressive delirium,
cognitive impairment, ± seizures and fever (often with CMV
disease elsewhere) CT/MRI may show periventricular
abnormalities.
Rapid (days to <4 weeks) syndrome with progressive
delirium, cognitive impairment, ± seizures and fever (often
with CMV disease elsewhere) CT/MRI may show
periventricular abnormalities and CSF PCR positive for CMV
HSV mucocutaneous
ulceration
None Persistent ulceration for >1 month, plus histology or
culture or detection of antigen or HSV PCR positive from
affected tissue
HSV visceral disease (for
example, oesophagitis,
pneumonitis
None Symptoms, plus histology or culture or detection of
antigen or HSV PCR positive from affected tissue
VZV multidermatomal ≥10 typical ulcerated lesions affecting at least two
noncontiguous dermatomes plus response to an antiviral
active against VZV unless resistance is demonstrated
≥10 typical ulcerated lesions affecting at least two
noncontiguous dermatomes plus culture or detection of
antigen or VZV PCR-positive from affected tissue
Histoplasmosis,
disseminated or
extrapulmonary
None Symptoms plus histology or culture or detection of
antigen from affected tissues
Isosporiasis None Persistent diarrhoea for >1 month, histology or microscopy
Leishmaniasis, visceral None Symptoms plus histology
Microsporidiosis None Persistent diarrhoea for >1 month, histology or microscopy
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Table 5 Presumptive and definitive criteria for AIDS-defining events (Continued)
MAC, and other atypical
mycobacteriosis
Symptoms of fever, fatigue, anaemia or diarrhoea plus acid-fast
bacilli seen in stool, blood, body fluid, or tissue but not grown
on culture and no concurrent diagnosis of TB except
pulmonary
Symptoms of fever, fatigue, anaemia or diarrhoea plus
culture from stool, blood, body fluid, or tissue
Tuberculosis, pulmonary Symptoms of fever, dyspnoea, cough, weight loss, fatigue plus
acid-fast bacilli seen in sputum, lavage, or lung tissue, not
grown in culture, plus responds to standard TB treatment
Symptoms of fever, dyspnoea, cough, weight loss,
fatigue plus positive TB culture or PCR from sputum,
bronchial lavage, or lung tissue
Tuberculosis,
extrapulmonary
Symptoms, plus acid-fast bacilli seen from affected tissue or
blood but not grown in culture, concurrent diagnosis of pul-
monary TB or responds to standard TB treatment
Symptoms, plus positive TB culture or PCR from affected
tissue
Nocardiosis Clinical evidence of invasive infection plus microscopic
evidence of branching, Gram-positive, weakly acid-fast bacilli
from affected tissue
Clinical evidence of invasive infection plus positive
culture from blood or affected tissue
Penicillium marneffei
disseminated
Characteristic skin lesions plus response to antifungal therapy
for penicilliosis (in an endemic area)
Culture from a nonpulmonary site
Pneumocystis pneumonia
(PCP)
Symptoms, any CXR appearance and CD4 count <200,
negative bronchoscopy if treated for PCP for >7 days, no
bacterial pathogens in sputum, and responds to PCP treatment
Microscopy or histology
Extrapulmonary
pneumocystis
None Symptoms plus microscopy or histology
Recurrent bacterial
pneumonia
Second pneumonic episode within 1 year, new CXR
appearance, symptoms and signs, diagnosed by a doctor
Second pneumonic episode within 1 year, new CXR
appearance, detection of a pathogen
Progressive multifocal
leukoencephalopathy
(PML)
Symptoms and brain scan consistent with PML and no
response to treatment for toxoplasmosis
Symptoms and brain scan consistent with PML and
positive JC virus PCR in CSF or histology
Rhodococcus equi disease None Clinical evidence of invasive infection plus culture of
organism from blood or affected tissue
Recurrent Salmonella
septicaemia
None Second distinct episode, culture confirmed
Cerebral toxoplasmosis Symptoms of focal intracranial abnormality or decreased
consciousness, and brain scan consistent with lesion(s) having
mass effect or enhancing with contrast, and either positive
toxoplasma serology or response to treatment clinically and by
scan
Histology or microscopy
Extra-cerebral
toxoplasmosis
None Symptoms plus histology or microscopy
Neoplasms
Kaposi sarcoma (KS) Typical appearance without resolution. Diagnosis should be
made by an experienced HIV clinician
Histology
Cervical carcinoma,
invasive
None Histology
Lymphoma, primary
cerebral
Symptoms consistent with lymphoma, at least one lesion with
mass effect on brain scan, no response to toxoplasma
treatment clinically and by scan
Histology
Lymphoma, non-
Hodgkin B cell
None Histology
lymphoma, Hodgkin None Histology
Neurologic
HIV encephalopathy Cognitive or motor function interfering with usual activity,
progressive over weeks or months in the absence of another
condition to explain the findings. Should have a brain scan ±
CSF examination to exclude other causes.
None
Other
Indeterminate cerebral
lesion (s)
Neurologic illness, with evidence for an intracerebral lesion by
brain scan, where the differential diagnosis is either cerebral
toxoplasmosis. PML, cerebral lymphoma, or HIV encephalopathy
Based on 1993 Revised CDC classification system (MMWR 1992; 41(RR-17): 1-19) and modified for this trial.
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will be followed for study patients. Tapering the dose of
corticosteroids reduces the risk of adrenal suppression.
Study drug should only be stopped immediately in two
circumstances:
1. if the patient has received four or fewer doses of the
study drug, or
2. if the study drug is being replaced by other
corticosteroid therapy
In all other circumstances, study drug will be stopped
by using dose tapering by moving the patient’s treatment
forward on the dosing schedule, as illustrated below: (for
example, if the patient is in week 3 of treatment, he or
she should be moved immediately onto the week 4 dose,
and then continue treatment as per the dose-tapering
schedule with weekly reductions in the treatment dose)
(Figure 4).
Any changes in patient’s medication must be recorded
on the CRF and on the concomitant medication form.
Indications for stopping study drug/placebo
The main indication to stop the study drug is if the patient
develops a condition for which there is good evidence that
steroids are beneficial and should be prescribed. Examples
of this are as follows:
1. Tuberculous meningitis: Dexamethasone has been
demonstrated in a large randomised controlled trial
to reduce the risk of death [10]. If a patient develops
TB meningitis, the study drug should be stopped,
and the patient should receive the appropriate
dosage of steroids according to the severity of the
disease. This does not necessitate unblinding of
treatment allocation.
2. Intracranial space-occupying lesion with mass
effect: For example, a primary brain tumour such as
CNS lymphoma. Space-occupying lesion with mass
effect is generally considered to be an indication
for steroid therapy. A typical dose would be
dexamethasone, 4 mg, 4 times daily. The study drug
should be stopped in all patients, and the patient
should receive corticosteroid treatment as per local
guidelines. This does not necessitate unblinding of
treatment allocation.
Note: a suspected cryptococcoma is not an
indication to alter the study drug; we do not know
whether dexamethasone is indicated in this case,
and the study is testing this indication.
3. Severe pneumocystis pneumonia (PCP): All
patients in the study must receive PCP prophylaxis
with co-trimoxazole; this reduces the risk of developing
PCP. However, PCP may still occur. Microbiologic
confirmation of PCP is not always possible, and the
diagnosis is often made on clinical grounds. The chest
radiograph typically shows bilateral interstitial, often
perihilar, shadowing. The differential diagnosis of this
appearance includes bacterial pneumonia and acute
respiratory distress syndrome (ARDS) due to
cryptococcosis. The gold standard for diagnosis of PCP
is to demonstrate the presence of Pneumocystis jirovecii
in bronchoalveolar lavage washings or in induced
sputum samples. Severe PCP is confirmed when there
is a typical clinical syndrome is present AND the
arterial blood oxygen partial pressure (pO2) is less than
70 mm Hg (FiO2 ≥ 20%). Prednisolone (40 mg twice
daily for 5 days, 40 mg once daily for 5 days, followed
by 20 mg/day for 11 days), in combination with high
dose co-trimoxazole, has been shown to reduce the risk
of death from severe PCP [41]. Where arterial blood
gas measurement is not available, diagnosis of severe
PCP should be made in accordance with local
guidelines. In any patient in whom the diagnosis of
severe PCP is made, the study drug must be stopped
Figure 4 Dose tapering in the event of stopping study drug.
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immediately, and the patient treated with prednisolone
in conventional doses, and high dose co-trimoxazole
as per local guidelines. This does not necessitate
unblinding of treatment allocation.
Any changes to study medication will be recorded in
the case-record form.
Unblinding
Unblinding means revealing the identity of the study treat-
ment (that is, dexamethasone or placebo). Treatment allo-
cation should be unblinded only if knowing the treatment
that a patient has been allocated will result in a change in
the patient’s management. The need to unblind is likely to
be rare during the study. Unblinding a patient’s treatment
allocation does not enable us to tell if a particular adverse
event is due to the investigational agent; that conclusion
can be drawn only with an analysis of all available data, ei-
ther at an interim safety analysis (which is done by the in-
dependent data and safety-monitoring board) or after the
final analysis of the study.
Process for unblinding
The decision whether to unblind should be discussed
with the lead country investigator or the principal inves-
tigator, when possible. Unblinded treatment allocation
should be held securely at each site and be available at
all times. The responsibility to approve unblinding will
be assigned to dedicated staff at each site. Access to
treatment allocation should be given only with the ap-
proval of one of these dedicated staff. Unblinding will be
documented in the case-record form.
Data on concomitant medications
At each visit, information on other medications, includ-
ing start dates and reason for taking them, will be docu-
mented in the case-record forms.
Withdrawal from the trial
Patients may voluntarily withdraw from the trial for any
reason. If this occurs, the patient will be referred to
standard clinical care facilities. The patient’s withdrawal
from the trial will not affect the access to the best stand-
ard of care within the local health system. With the
agreement of the patient, clinical and laboratory assess-
ment should be performed and recorded at the time of
withdrawal. Patients may also decide to stop study treat-
ment without withdrawing from the study, in which
case, treatment will be adjusted as described later, and
follow-up will continue as per the study schedule.
Provided no more than 4 days of study drug have been
administered, if a patient wishes to withdraw, the study
drug can be stopped immediately. If a patient has re-
ceived 5 or more days of study drug, then it is possible
that adrenal suppression has occurred, and the dose of
dexamethasone should be tapered. Thus, if a patient
wants to withdraw from the study, and has received 5 or
more days of study drug, then the withdrawal phase of
steroid dosing will be started immediately; the patient
will be switched to the next dexamethasone dose in the
steroid-dosing sequence. For example, if on day 16, a pa-
tient wants to leave the study, then he or she will be im-
mediately switched to the next phase of steroid/placebo
dose (3 mg/day), and the treatment tailed off according
to the treatment schedule (Table 4). This continuation
of treatment after withdrawal will be fully explained in
the informed-consent form. Follow-up will be according
to clinical need. All patients in the study will be pro-
vided with steroid information cards in their own lan-
guage. These will detail the need to reduce the dose
gradually if they are to be stopped, and to inform other
health care workers that they are taking dexamethasone,
should they require treatment from a health care worker
not involved with the trial. If the patient has an un-
scheduled period off treatment or not in follow-up, this
should be recorded in the case-report forms.
Definition and assessment of adverse events
Definition of adverse events
An adverse event (AE) is any undesirable event that oc-
curs to a study participant during the course of the
study, regardless of whether that event is considered re-
lated to the study drug. An AE can, therefore, be any un-
favourable and unintended sign (including an abnormal
laboratory finding, for example), symptom, or disease
temporally associated with the study drug, whether or
not considered related to the study drug.
Examples include the following:
 An increase in severity or frequency of a preexisting
abnormality or disorder (events that are marked by
a change from the participant’s baseline/entry status)
 All reactions from sensitivity or toxicity to study drug
 Injuries or accidents (for example, for a fall
secondary to dizziness, “dizziness” is the event and
the injury secondary to the fall is the “outcome”)
 New clinically significant abnormalities in clinical
laboratory values, physiological testing, or physical
examination.
Stable chronic conditions, such as arthritis, which are
present before clinical trial entry and do not worsen are
not considered AEs and will be documented in the sub-
ject’s clinical chart as medical history.
Clinical or laboratory events are considered adverse
events only if they occur after the first dose of study
treatment and before the patient completes trial partici-
pation. (See later for reporting of adverse events.)
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Definition of serious adverse events
An AE is considered to be "serious" if it results in one of
the following outcomes
 Death,
 Life-threatening event (the subject was at immediate
risk of death at the time of the event; it does not
refer to an event that hypothetically might have
caused death if it were more severe),
 Inpatient hospitalisation or prolongation of existing
hospitalisation
 Persistent or significant disability/incapacity
(a substantial disruption of a person's ability to
conduct normal life functions),
 Congenital anomaly/birth defect,
 Important medical event that may not be
immediately life-threatening or result in death or
hospitalisation but may jeopardise the patient or
may require intervention to prevent one of the other
outcomes listed in the earlier definition.
Definition of unexpected serious adverse events
Unexpected serious adverse events are untoward med-
ical events that fit one or more of the previously ex-
plained criteria for SAEs and that are not considered a
part of normal clinical progression of disease or an ex-
pected drug reaction. Any event that becomes of con-
cern to the investigators or study doctors during the
course of the trial may be reported as a USAE.
Assessment of adverse events
Adverse events will be defined according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE)
definitions: http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/ctc.htm. New AIDS-defining events
will be defined according to the revised CDC criteria
modified for this trial (see Table 5, and Appendix 6). In
the event that an adverse event is not described within the
CTCAE definitions, or a new AIDS-defining event, as
defined in Table 5, the following generic severity grading
will be used:
Grade 1 Mild; asymptomatic or mild symptoms;
clinical or diagnostic observations only; intervention
not indicated.
Grade 2 Moderate; minimal, local, or noninvasive
intervention indicated; limiting age-appropriate
instrumental Activities of Daily Living (ADLs)*.
Grade 3 Severe or medically significant but not
immediately life-threatening; hospitalisation or
prolongation of hospitalisation indicated; disabling;
limiting self-care ADL**.
Grade 4 Life-threatening consequences; urgent
intervention indicated.
*Instrumental ADLs refer to preparing meals, shopping
for groceries or clothes, using the telephone, managing
money, and so on.
**Self-care ADLs refer to bathing, dressing and
undressing, feeding self, using the toilet, taking
medications, and not bedridden.
Details on the grading of specific adverse events can
be found in Appendix 6. [Note: “Life-threatening” as a
severity grade is not necessarily the same as “life-threat-
ening” as a “serious” criterion used to define a serious
adverse event. The former is a “potential” threat to life,
and the latter is an “immediate” threat to life.]
A laboratory abnormality must be recorded as a clin-
ical adverse event only if it is associated with an inter-
vention. Intervention includes, but is not limited to,
discontinuation of a current treatment, dose reduction/
delay of a current treatment, or initiation of a specific
treatment. In addition, any medically important labora-
tory abnormality may be reported as an adverse event at
the discretion of the investigator. This would include a
laboratory result for which no intervention is needed,
but the abnormal value suggests a disease or organ tox-
icity. Laboratory events will be graded according to
CTCAE definitions.
If clinical sequelae are associated with a laboratory ab-
normality, the diagnosis or medical condition should be
reported as the adverse event (for example, renal failure,
haematuria), not the laboratory abnormality (for ex-
ample, elevated creatinine, urine RBC increase).
Recording and reporting of adverse events and
protocol violations
Adverse event recording
Grade 3 and 4 adverse events will be recorded in the
case report form and entered into the study database.
Grade 1 and 2 events will not be recorded, because in a
severe disease such as CM, the number of low-grade ad-
verse events is likely to be high, representing a large
reporting burden, which may affect the quality of re-
cording and reporting of more important grade 3 and 4
adverse events.
Adverse event reporting
Serious adverse events and serious unexpected adverse
events will be reported to the Principal Investigator
within 7 days of occurrence, or sooner, according to
local requirements. The Principal Investigator will report
all unexpected serious adverse events to the DMEC
within 10 days of occurrence. Unexpected serious ad-
verse events will be reported to the responsible ethical
committees within 10 days of occurrence, or as required
by the committee.
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Protocol violations
Protocol violations are events that contradict or omit
protocol instructions. Violations that compromise pa-
tient safety or the integrity of trial data will be recorded
and reported to the responsible Ethics Committees, as
required by the regulations of each Committee.
Statistics
Sample size and power considerations
The trial is powered for the primary end point (that is,
overall survival during the 10-week follow-up period).
Few data exist on which to estimate the potential ef-
fect size of dexamethasone on mortality from CM. We
have based our estimate of the effect size on data from
tuberculous meningitis, which shares clinicopathologic
features with CM. In a large RCT of dexamethasone to
treat tuberculous meningitis in Vietnam, the hazard ratio
(HR) for death was 0.69 at 9 months in favour of dexa-
methasone [25]. Most of this effect occurred during the
first 3 months of treatment. The dose of dexamethasone
we will test is the same as that used in that trial. Add-
itionally, in a study of dexamethasone in bacterial men-
ingitis in Vietnam, the HR was 0.43 in patients with
microbiologically confirmed disease, and 0.59 in a study
based in Europe, again in favour of dexamethasone
[34,35]. These analyses were all based on the intention-
to-treat principle (including noncompliant patients), and
it seems sensible to expect a similar rate of noncompli-
ance in our study. Therefore, we believe a target hazard
ratio of 0.7 in favour of dexamethasone to be reasonable
for our trial.
To detect such a risk reduction of 30% with 80%
power at the two-sided 5% significance level, a total of at
least 247 deaths must be observed. Based on historical
data and consultation with principal investigators from
all study sites, the 10-week mortality risk in the control
group is expected to be between 30% and 50% [38], and
the target hazard ratio of 0.7 corresponds to absolute
risk reductions in mortality from 30% to 22%, or from
50% to 38%. Assuming an overall 10-week mortality of
at least 30% in our study population, recruitment of 824
patients is sufficient to observe the target number of
deaths. Allowing for some loss to follow-up, the total
sample size for this study is 880 patients.
A major aim of this trial is to generate robust evidence
across both continents. To achieve this goal, we aim to
recruit roughly similar numbers of patients from each
continent.
Event-driven stopping of the trial after 247 observed
deaths is not foreseen even if this should occur prior to
recruiting 880 patients. Thus, the study will be conserva-
tively powered if the study mortality is larger than 30%.
For example, if overall mortality was around 50% and
412 deaths were observed during the study, power would
increase to 95% for a true hazard ratio of 0.7 and to 83%
for a true hazard ratio of 0.75.
Analysis
Analysis of the primary end point and 6-month mortality
The analysis will be based on a stratified Cox propor-
tional hazards model allowing for separate baseline haz-
ards for each continent (Asia or Africa) and treatment
allocation as the only covariate. The stratification is
based upon the expectation of different mortalities in
the control arm by continent but similar (relative) effects
of the intervention across continents. The proposed test
is essentially equivalent to using a stratified log‐rank test
to compare the two treatment arms. We prefer to use
the Cox model as it automatically provides treatment ef-
fect estimates and confidence intervals in addition to the
P value.
In a second stage, overall survival will be modelled
by using the Cox proportional hazards regression
model with stratification by continent and the follow-
ing covariates (in addition to the treatment group):
country, baseline fungal load, Glasgow coma score less
than 15, and ARV status at study entry (ARV naïve or
experienced).
Potential heterogeneity of the treatment effect will be
assessed based on appropriate interaction (likelihood ra-
tio) tests and the following predefined subgrouping
variables:
 Continent
 Country
 IDSA indications for steroid treatment at baseline
(cryptococcoma with mass effect, acute respiratory
distress syndrome or IRIS: yes or no)
 Glasgow coma score <15 (yes or no)
 Naïve to ARVs at study entry versus on ARVS at
study entry
All Cox regressions and sub-group analyses will be
performed for the primary end point (10-week survival)
as well as for 6-month survival. Kaplan-Meier plots and
explicit survival estimates at 10 weeks and 6 months of
follow-up will also be calculated for the full populations
and for each continent separately.
Analysis of secondary end points
Neurologic disability The disability score at week 10 and
month 6 of follow-up is defined as the higher (worse) of
the “simple question” and the Rankin score assessed at
that time point and will be categorised as good outcome,
intermediate disability, severe disability, or death (in case
the patient died before the respective time point) as previ-
ously described [10] (also see Table 1). The proportion of
patients with a good outcome will be compared between
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the two arms with a logistic regression adjusted for contin-
ent (in addition to the treatment arm). Patients lost to
follow-up will be analysed according to their last recorded
disability status. If the rate of patients lost to follow-up ex-
ceeds 10%, we will also perform an alternative analysis
based on multiple imputation of missing values.
Rate of CSF sterilisation during the first 2 weeks
(based on available data from selected sites only)
Fungal decline in the first 14 days will be modelled with a
joint model for longitudinal and survival data. The longitu-
dinal part of the model will be a linear mixed-effects model
with longitudinal log-CSF quantitative culture fungal counts
as the outcome, continent and interaction terms between
the treatment groups and the time since enrolment of the
measurement as fixed covariates, and a random patient-
specific intercept and slope. The survival part of the joint
model models mortality up to 2 weeks depending on the
treatment group, continent, and the patient-specific random
intercepts and slopes. The survival part acts as a missing
data mechanism to allow potentially informative truncation
of quantitative count measurements due to death.
Longitudinal measurements of intracranial pressure dur-
ing the first 2 weeks will be modelled in the same way.
Adverse events The frequency of serious and grade 3
and 4 adverse reactions as well as the frequency of spe-
cific adverse events will be summarised (both in terms
of the total number of events as well as the number of
patients with at least one event). The proportion of pa-
tients with at least one such event (overall and for each
specific event separately) will be summarised and (infor-
mally) compared between the two treatment groups
based on the Fisher Exact test.
The rate of IRIS and the rate of relapse (defined as
antifungal treatment intensification or re-treatment) will
be modelled with cause-specific proportional hazards
models stratified by continent, taking into account the
competing risk of prior death. Cumulative incidence func-
tions for the competing events will also be calculated and
displayed by treatment arm. Secondary time-to-event end
points (time to new AIDS-defining illness or death and
time to new neurologic event or death) will be analysed
with Kaplan-Meier curves and Cox regression models, as
described for the primary end point expressed earlier. The
proportion of patients with blindness or visual deficit will
be compared between the two arms with a logistic regres-
sion (as for the proportion of patients with good disability
described earlier).
Analysis populations
The primary analysis population for all analysis is the
full analysis population containing all randomised pa-
tients except for those mistakenly randomised without
CM. Patients will be analysed according to their rando-
mised arm (intention-to-treat). In addition, the primary
end point will be analysed on the per-protocol popula-
tion, which will exclude the following patients: major
protocol violations and those receiving less than 1 week
of administration of the randomised study drug for rea-
sons other than death.
Interim analysis and role of the Data Monitoring
and Ethical Committee (DMEC)
An independent DMEC will oversee the trial. Unexpected
serious adverse events with treatment allocation blinded
will be reported to the DMEC within 10 days of occur-
rence and followed up until resolution. The DMEC will
perform formal interim analyses after every 50 deaths.
According to the sample-size calculations, we expect to
observe around 247 deaths during the course of the study.
Thus, four to five planned formal interim analyses after
50, 100, 150, 200, and (possibly) 250 deaths will take place.
At these interim analyses, the DMEC will receive a re-
port including unblinded summaries of mortality, serious
adverse events, grade 3 and 4 adverse events, and esti-
mates of the rate of CSF sterilisation during the first
14 days (from selected sites only) by treatment arm. The
report will be prepared by the DMEC statistician and dis-
tributed to all DMEC members for review. Based on these
data, the committee will make recommendations on the
continuation, cessation or amendment of the study. The
study statistician will remain blinded throughout the study
but will aid in setting up the code for generating the in-
terim analysis summaries. The randomisation list will be
sent to the DMEC statistician directly from the study cen-
tral pharmacist.
Stopping for efficacy of dexamethasone at an interim ana-
lysis is foreseen only if the benefit of adjuvant treatment
with dexamethasone is shown “beyond reasonable doubt.”
The Haybittle-Peto boundary, requiring P <0.001 at interim
analysis to consider stopping for efficacy, will be used as
guidance. Stopping for harm of dexamethasone should be
considered if an unfavourable trend emerges, sufficiently
large to rule out a clinically relevant benefit of dexametha-
sone. Conclusive evidence that dexamethasone is harmful
is not sought, as continued exposure of patients to a nonbe-
neficial novel treatment that could be harmful appears to
be unethical. To support the DMEC decision, the DMEC
will receive conditional power curves in addition to the
summaries described earlier. Conditional power assesses
the probability that a benefit of dexamethasone will even-
tually be detected, conditional on the data accrued so far. If
this probability is low for a wide range of reasonable as-
sumed treatment effects (including the target hazard ratio
of 0.7 from the original sample-size calculation), this sug-
gests little reason to continue the trial because the treat-
ment is unlikely to show benefit.
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Importantly, the DMEC recommendations will not be
based purely on statistical tables but will also use clinical
judgment.
As the dissemination of preliminary summary data could
influence the further conduct of the trial and introduce
bias, access to interim data and results will be confidential
and strictly limited to the involved independent statistician
and the monitoring board, and results (except for the rec-
ommendation) will not be communicated to the outside
and/or clinical investigators involved in the trial.
Further reviews will be at the discretion of the DMEC
or the request of the Trial Steering Committee. All
DMEC reports, replies, or decisions will be sent to the
Trial Steering Committee and the responsible Research
Ethical Committees.
Ethical considerations
Declaration of Helsinki and good clinical practice
The Investigator will ensure that this study is conducted
in compliance with the current revision of the Declar-
ation of Helsinki (Seoul 2008) and the Medical Research
Council Guidelines on Good Clinical Practice (1998).
Ethical review
The Oxford University Tropical Research Ethics Com-
mittee (OxTREC) is the ethical committee of reference
for this trial. The study protocol and its associated docu-
ments were submitted to OxTREC and all other ethical
committees, as required by local regulation at each site.
Ethical approval has been obtained from:
 OxTREC, Oxford, UK 25-12
 Ministry of Health, Vietnam
 Hospital for Tropical Diseases, Ho Chi Minh City,
Vietnam
 Ministry of Health, Laos 039/NECHR
 Faculty of Medicine, Universitas Indonesia,
Indonesia 623/H2.F1/ETIK/2012
 Mahidol University, Thailand MUTM 2012-051-01
 Institute for the Development of Human Research
Protections,
Thailand 04CN
 Uganda Council for Science and Technology
HS1264
 National Drug Authority, Uganda 020/ESR/NDA/
DID-01/2013
 Ministry of Health, Malawi #1077
 Pharmacy, Medicines and Poisons Board, Malawi
PMPB/CTRC/111/3105201354
 University of Toronto, Canada 28199
The principal investigator will submit and obtain approval
where necessary from the ethical committee of reference
and the responsible local committees for all substantial
amendments to the original approved documents. Annual
reviews of the trial will be conducted by the ethical commit-
tee of reference and as required by all other committees.
Informed consent
The study staff will discuss the study with all potential
adult participants or, in the case of a participant who is un-
able to give informed consent independently, with a repre-
sentative appropriate within the local culture. Study staff
will describe the purpose of the study, the study proce-
dures, possible risks/benefits, the rights and responsibilities
of participants, and alternatives to enrolment. The partici-
pant or representative will be invited to ask questions that
will be answered by study staff, and they will be provided
with appropriate numbers to contact if they have any ques-
tions subsequently. If the participants or representatives
agrees to participate, they will be asked to sign and date an
informed consent form. A copy of the form will be given
to them to keep. If required, the participant or representa-
tive will be given up to 24 hours to consider the study, pro-
vided the participant remains eligible for the study.
Participants whose consent was given by a representa-
tive will be approached to consider consent independ-
ently, if at any time during study participation he or she
becomes able to consider consent independently.
In addition to these procedures, illiterate signatories will
have the informed-consent form read to them in the pres-
ence of a witness who will sign to confirm that the form
was read accurately and that the participant or representa-
tive agrees to participation. All patient-information sheets
and Consent/Assent forms will be written in the local lan-
guage and will use terms that are easily understandable.
Clinical care will not be delayed in any case during consid-
eration of consent.
Risks
This study will use a drug that has been studied thor-
oughly and its toxicities are well described. Details can be
found in the Study Treatment section of this protocol.
Patients will be closely monitored for all adverse events
and treated as per standard of care. Additional volumes of
blood and cerebrospinal fluid will be taken for research
tests. These volumes have very little risk of affecting the
participant’s health. Some phlebotomy may be performed
more often than is required by clinical care. This proced-
ure carries the small risk of bruising and infection.
Dexamethasone may be growth suppressing in children
and fetuses. Therefore, children and pregnant women have
been excluded from this trial.
Benefits
It is unknown whether study participants who receive
study treatment will benefit. The additional monitoring
and follow-up of patients by dedicated study staff may
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be of benefit to patients treated in resource-limited set-
tings. Treatment costs for trial participants will be sup-
ported, including payment of all study treatment and
standard antifungal treatment.
Training in laboratory and clinical procedures, re-
search methods, and good clinical practice, will be given
to all participating centres. Investigators will engage with
the HIV/AIDS community in each setting to ensure that
trial conduct is cohesive with local patient-support
services.
Alternatives to study participation
The alternative to participation in this study is routine
care by the doctors in the hospital. Patients will be re-
sponsible for their own treatment costs as per local
norms and hospital policy.
Confidentiality
Participants will be assured that all information gener-
ated in this study will remain confidential. The trial staff
will ensure that the participants’ anonymity is main-
tained. Participant’s names will be recorded at the time
of enrolment to allow their identification at follow-up
visits. However, identifiable information will be linked to
stored data or samples only by a protected Master List.
This list will not be shared outside the study staff. All
documents will be stored securely, and all reports or
samples will be coded without identifying information.
Direct access will be granted to authorised representa-
tives from the host institution and the regulatory author-
ities, if applicable, to permit trial-related monitoring and
inspections.
Withdrawal of participants from the study
Each participant has the right to withdraw from the study
at any time. All patients who withdraw will be referred for
treatment as per routine clinical care. The reason for with-
drawal will be recorded in the CRF. Study drug will be
managed as detailed under Stopping Study Drug.
Sample sharing and storage
Samples collected will be used for the purpose of this
study as stated in the protocol and stored for future use
in studies not yet conceived, which may include genetic
studies. Consent will be obtained from subjects for gen-
etic testing and for sample storage and/or shipment of
specific samples to collaborating institutions for investi-
gations that cannot be performed locally. Any proposed
plans to use samples other than for those investigations
detailed in this protocol will be submitted to the relevant
ethics committees before any testing.
The participants will be identified only by a study-
specific participant number and/or code in any database.
The name and any other identifying detail will not be in-
cluded in any study data electronic file.
Sponsorship and insurance
The University of Oxford has appropriate insurance-
related arrangements in place in respect of the University's
role as research sponsor for this study.
Data
Data collection and entry
Source documents will be generated during the study by
the site study staff at participating institutions. Source
documents include all original recordings of observations
or notations of clinical activities, and all reports and re-
cords necessary for the evaluation and reconstruction of
the clinical trial. Source documents include, but are not
limited to, the subject’s medical records, research case rec-
ord forms (paper or electronic), laboratory reports, ECG
tracings, x-rays, radiologist’s reports, subject’s diaries and
questionnaires, biopsy reports, ultrasound photographs,
progress notes, pharmacy records, and any other similar
reports or records of procedures performed during the
subject’s participation in the study.
Access to applicable source documents is required for
study purposes. The site investigators are responsible for
maintaining any source documentation related to the
study. Source documentation should support the data
collected on the CRF when the CRF is not the original
site of recording. Source documentation must be avail-
able for review or audit by the sponsor or designee and
any applicable regulatory authorities.
Case Report Forms (CRFs) will be used as a data col-
lection tool. The study team will transfer the informa-
tion from the source documents onto the CRFs. CRFs
may be used as source documents if they are the pri-
mary data-collection tool for specified data, as docu-
mented in written standard operating procedures. The
site Investigators are responsible for maintaining accur-
ate, complete, and up-to-date records. These forms are
to be completed on an ongoing basis during the course
of the study by authorised individuals.
Corrections to paper CRFs must be initialled and dated
by the person making the correction and must not obliter-
ate the original entry. All CRFs should be reviewed by the
designated study staff and signed as required with written
or electronic signature, as appropriate.
Selected study members (study doctors or nurses) will
be trained on how to enter all clinical data as source in-
formation from the CRFs and from laboratory source
documents into an Internet-based computerised data-
entry system called CliRes hosted by OUCRU Viet Nam.
Data entry will occur simultaneously, as data are being
generated during the trial as soon as possible after the
information is generated. Data may be manually entered
Day et al. Trials 2014, 15:441 Page 21 of 28
http://www.trialsjournal.com/content/15/1/441
or scanned and electronically uploaded, dependent on
available software. Source documents and electronic data
will be verified according to the Trial Monitoring Plan.
After study completion and the main analyses and
publication of the study results, the study sub-datasets
consisting of the patient data from particular recruiting
sites will be available to the investigators from those
sites.
Record retention
The investigator is responsible for retaining all essential
documents listed in the MRC guidelines on Good Clinical
Practice. All essential documentation for all study subjects
is to be maintained in original paper format by the investi-
gators in a secure storage facility for a minimum of 3 years
and as required by local regulations thereafter. All essen-
tial documentation will be converted from paper to elec-
tronic format (if required) and stored centrally for at least
10 years after the completion of the trial and as required
by local regulations thereafter. All stored records are to be
kept secure and confidential.
Monitoring
The trial will be conducted in compliance with this proto-
col, Medical Research Council Guidelines of Good Clinical
Practice, and any applicable regulatory requirement(s).
The study will be adequately monitored by the OUCRU
or their designate. Monitors will visit the clinical research
site to monitor all aspects of the study in accordance with
the appropriate regulations and the approved protocol.
The objectives of a monitoring visit will be (a) to verify the
existence of adequately signed informed-consent docu-
ments for each enrolled subject; (b) to verify the prompt,
complete, and accurate recording of all monitored data
points, and prompt reporting of all SAEs and unexpected
SAEs; (c) to compare abstracted information with individ-
ual subjects’ records and source documents (subjects’
charts, case report forms, laboratory analyses and test re-
sults, physicians’ progress notes, nurses’ notes, and any
other relevant original subject information); (d) to verify
the supply and condition of the study drug and the accur-
ate and secure assignment of randomisation code; and (e)
to ensure protection of study subjects, investigators’ com-
pliance with the protocol, and completeness and accuracy
of study records. The monitors also will inspect the
clinical site regulatory files to ensure that regulatory re-
quirements and applicable guidelines are being followed.
During the monitoring visits, the investigator (and/or des-
ignee) and other study personnel will be available to dis-
cuss the study progress and monitoring visit.
Discussion
The trial commenced recruiting patients in February
2013 and by the end of May 2014 had recruited 357
patients. Two interim analyses were made by an inde-
pendent data monitoring and ethics committee, as pre-
determined, and on both occasions, it was concluded
that the trial was being conducted well, and should con-
tinue. An investigators’ meeting was held in Vietnam to
develop the collaborative network, share best-practice
qualities, discuss recruitment strategies, and consider
opportunities for substudies.
Initially, the trial was designed to recruit 550 patients
from Asia and 330 from Africa (880 total) with the ra-
tionale being that the 10-week death rate in patients in
Vietnam would be 30%, and in Malawi, 50% [38], and
that the target hazard ratio of 0.7 corresponded to an
absolute risk reduction in mortality from 30% to 22%, or
from 50% to 38%. These national mortality rates were
assumed to be representative at the continental level,
and recruitment of 500 patients from Asia and 300 pa-
tients from Africa (800 patients in total) would have
been sufficient to observe the target number of deaths, a
total of 880, allowing 10% loss to follow-up.
As the trial progressed, it became apparent that this
strict division could hamper recruitment and was based
on information that suggested a larger difference between
Asian and African patients than was being observed in the
blinded data. After discussions amongst the investigators
and the trial steering committee, this requirement was re-
placed by a more-lenient statement that the study would
aim to recruit roughly similar numbers of patients from
each continent.
Publication
Any publication or presentation during the active phase
of the study must have permission from the Investiga-
tors. The investigators will define the strategy for publi-
cation, resolve any problems of authorship, and maintain
the quality of publications. All publications will acknow-
ledge the appropriate authors and funding sources ac-
cording to normal academic practice. The investigators
are the custodians of the data and specimens generated
from this trial.
Trial status
In total, 417 of 880 patients have been recruited by 6
August, 2014.
Appendix 1 Cryptococcal quantitative cultures,
cryptococcal archiving: standard operating
procedure
Aim
To describe how to safely undertake quantitative culture of
CSF for Cryptococci and how to store isolates as part of the
Cryptodex study (see Table 6 for safety considerations).
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Principle
Serial 10-fold dilutions of CSF are made, and a known vol-
ume is cultured on Sabouraud agar. After incubation, the
number of colonies growing is counted and used to calcu-
late the approximate numbers of Cryptococcus sp. in the
original sample. Initial isolates and any variants, including
those that might represent drug-resistant strains, are stored
by using a commercial system.
Equipment
1. Volumetric pipettes capable of delivering 100 μl
and 900 μl volumes
2. Sterile tips for these
3. Bottles containing 5 to 10 ml sterile water
4. Lidded plastic tubes for 1-ml volumes of CSF
dilutions (four per sample)
5. Sabouraud dextrose agar plates (five per sample)
6. Sterile 1.5 ml Eppendorf tubes for storing CSF
7. Storage boxes (Nalgene or other)
8. Pro-Lab Microbank Beads or :Protect” tubes for
archiving isolates
9. Safety cabinet (Class II)
10. Vortex
Method
1. Plate preparation
1.1 Dry the Sabouraud plates in an incubator (30°C)
for 30 minutes before use.
1.2 Mark each plate into two halves by using a
permanent marker.
1.3 Label each plate with
a. the trial study number (if this is not yet
known, use the patient's name and date
of birth or age),
b. the date the sample was taken,
c. the dilution: that is, Neat, 10-1, 10-2, 10-3,
10-4
2. Dilution preparation
2.1 Dispense 900 μl of sterile distilled water aseptically
into each tube in the Class II BSC, and fasten the
lid tightly.
2.2 Label each tube with the Study number and the
dilution (10-1, 10-2, 10-3, and 10-4).
3. Samples
3.1 Samples should be processed as soon as possible
after being taken. If any delay occurs, samples
should be refrigerated at 4° to 8°C.
3.2 All processing should take place in a Class II BSC.
Table 6 COSHH risk assessment - University of Oxford COSHH assessment form
Description of procedure Substances used
Semi-quantitative culture of CSF for HIV and storage of isolates Sabouraud’s agar
CSF
Cryptococcus sp.
Quantities used Frequency of use
Up to 8 ml CSF Daily
Hazards identified Could a less hazardous substance be
used instead?
1. Blood-borne viruses: CSF samples for this study will be from patients with HIV and possibly other
blood-borne viruses.
No
2. Cryptococcus neoformans var grubii and Cryptococcus gattii are ACDP category 2 organisms. They pose a
small risk of infection to workers, treatment is available, and there is no risk of person to person
transmission.
What measures have you taken to control risk? A laboratory coat, gloves and goggles or glasses must be worn at all times when working on
specimens. All patient samples and cultures should be handled within a Class II biological safety cabinet. All staff must be checked for hepatitis B
virus immunity before commencing work as per local procedures, and vaccinated as appropriate. In the event of a splash or other injury, work will be
stopped immediately, and local guidelines will; be followed.
Checks on control measures
Observation and supervision by senior staff.
Is health surveillance required? Training requirements:
No All staff to be trained in the above SOP
prior to use.
Emergency procedures: Waste disposal procedures:
Local guidelines for splashes and inoculation injuries. All waste will be autoclaved prior to
disposal.
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3.3 Neat and diluted samples should be vortexed
before every step to ensure even mixing (that is,
before making the next serial dilution and
before inoculating the plate).
3.4 Using the volumetric pipette and a fresh sterile
tip, take 100 μl of vortexed CSF and add it to
the tube marked 10-1.
3.5 Vortex the 10-1 dilution, remove 100 μl of this
dilution by using a fresh sterile tip and add it to
the tube marked 10-2.
3.6 Vortex the 10-2 dilution, remove 100 μl of this
dilution by using a fresh sterile tip, and add it to
the tube marked 10-3.
3.7 Vortex the 10-3 dilution, remove 100 μl of this
dilution by using a fresh sterile tip, and add it to
the tube marked 10-4.
4. Plate inoculation
4.1 Plates should be inoculated immediately after
making the serial dilutions.
4.2 Use the plates labelled as in section Study design.
4.3 Vortex the 10-4 dilution, take a fresh sterile
pipette tip, and immediately remove 100 μl and
use it to inoculate half the plate labelled 10-4 by
dispensing approximately 20 drops of 5 μl.
4.4 Repeat 4.3 for the other half of the plate.
4.5 Vortex the 10-3 dilution, take a fresh sterile
pipette tip, and immediately remove 100 μl and
use it to inoculate half the plate labelled 10-3 by
dispensing approximately 20 drops of 5 μl.
4.6 Repeat 4.5 for the other half of the plate.
4.7 Vortex the 10-2 dilution, take a fresh sterile
pipette tip, and immediately remove 100 μl and
use it to inoculate half the plate labelled 10-2 by
dispensing approximately 20 drops of 5 μl.
4.8 Repeat 4.7 for the other half of the plate.
4.9 Vortex the 10-1 dilution, take a fresh sterile
pipette tip, and immediately remove 100 μl and
use it to inoculate half the plate labelled 10-1 by
dispensing approximately 20 drops of 5 μl.
4.10 Repeat 4.9 for the other half of the plate.
4.11Vortex the Neat CSF, take a fresh sterile pipette
tip, and immediately remove 100 μl and use it
to inoculate half the plate labelled Neat by
dispensing approximately 20 drops of 5 μl.
4.12 Repeat 4.11 for the other half of the plate.
4.13 Incubate all plates at 30°C for 1 week.
5. Reading samples
5.1 Start a new recording sheet for each patient.
5.2 Record the patient’s study number on each sheet.
5.3 Read the plates on day 3, day 5, and day 7.
5.4 Count the colonies on each plate by holding the
plate over a dark background.
5.5 Record plates with confluent growth as ”confluent
growth.”
6. Calculating the results
6.1 Use the plate that has between 10 and 100 typical
Cryptococcus colonies on each side to perform
the count (if in doubt about the identity, do a
Gram stain and India ink). If no plate has more
than 10 colonies, then use the plate with positive
growth to estimate the fungal burden.
6.2 Count the number of colonies on both sides of
this plate, and calculate the average.
6.3Calculate the number of cfu/ml of CSF by
multiplying the number of colonies by 10 (as only
100 μl was cultured) and then by the dilution
factor (that is, 20 colonies on Neat plate =20 ×
10 × 100 = 200 cfu/ml
○ 20 colonies on 10-1 plate =20 × 10 × 101 =
2,000 cfu/ml
○ 20 colonies on 10-2 plate =20 × 10 × 102 =
20,000 cfu/ml
○ 20 colonies on 10-3 plate =20 × 10 × 103 =
200,000 cfu/ml
○ 20 colonies on 10-4 plate =20 × 10 × 104 =
2,000,000 cfu/ml
7. Archiving samples
7.1 The first available C. neoformans growth for each
patient should be archived by using the locally
preferred method (for example, Pro lab Microbank
beads, “Protect” tubes or TSB +20% glycerol).
7.2 Use the Neat sample from Day 1 (or a later day
of the study if no Day 1 sample is available).
7.3 Run the sterile loop through all the colonies from
each side of the Neat culture plate and inoculate
the beads as per the manufacturer's instructions.
Run the loop through all the colonies rather than
using a single colony because Cryptococcus
populations within patients may be heterogeneous.
7.4 Repeat for the other side of the plate with a new set
of beads (so two sets of each sample are archived).
7.5 If colonies of different morphology are from the
same plate, then archive these separately, and
describe them on the tube label (for example,
patient XXXX, “smooth colony,” and Patient
XXXX “irregular colony.”
7.6 Label each bead tube with the study number, ”C.
neoformans” and the date that the sample WAS
TAKEN FROM THE PATIENT (not the date it
was cultured or archived).
7.7 Try not to use a plate if it is contaminated with
mould; - subculture first if no mould-free plates
are available.
7.8 Most patients will need only the earliest available
sample to be archived, but please also archive
the isolate from any sample where increasing
growth is present throughout the course of
treatment (for example, if the day 14 sample has
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a higher colony count than the day 7, please
also archive the day 7 and day 14 colonies).
Appendix 2 Definition of cryptococcal meningitis-
associated immune reconstitution syndrome
Case definition for paradoxical cryptococcal immune
reconstitution inflammatory syndrome in HIV patients
Antecedent requirements
 Taking antiretroviral therapy
 Cryptococcal disease diagnosed before ARV by
positive culture or typical clinical features plus
positive India ink staining or antigen detection
 Initial clinical response to antifungal therapy with
partial or complete resolution of symptoms or
signs, fever, or other lesions, or reduction in CSF
cryptococcal antigen concentration or quantitative
culture
Clinical criteria
 Event occurs within 12 months of ARV initiation,
reintroduction, or regimen switching after previous
failure
 Clinical disease worsening with one of the following
inflammatory manifestations of cryptococcosis:
 Meningitis
 Lymphadenopathy
 Intracranial space-occupying lesion or lesions
 Multifocal disease
 Cutaneous or soft-tissue lesions
 Pneumonitis or pulmonary nodules
Other explanations for clinical deterioration to be
excluded
 Non-adherence or suboptimum antifungal therapy,
indicated by an increase in quantitative culture or
antigen titer, or any positive cryptococcal culture
after 3 months of antifungal therapy
 Alternative infection or malignant disease in the
affected site
 Failure of ART excluded if possible (for example,
failure to achieve ≥1 log10 viral load by 8 weeks of
ARV)
ARV, antiretroviral therapy; CSF, cerebrospinal fluid.
Appendix 3: Management of increased
intracranial pressure
Increased intracranial pressure is a frequent complica-
tion of cryptococcal meningitis. The mechanism is not
clear, but probably is a combination of impaired CSF
drainage, increased CSF production, cerebral oedema,
and inflammation. Adults have approximately 175 ml of
cerebrospinal fluid, and the 24-hour production of CSF
is on the order of 550 ml. The normal CSF pressure re-
corded by lumbar puncture with the patient reclining in
the left lateral position is 5 to 18 cm of CSF. Few data
guide the management of increased intracranial pressure
in patients with cryptococcal meningitis, but the recom-
mendations of the IDSA guidelines are that the CSF
pressure should be identified at baseline. If the CSF
pressure is ≥25 cm of CSF and symptoms of increased
intracranial pressure are present during induction ther-
apy, relieved by CSF drainage (by lumbar puncture, re-
duced the opening pressure by 50% if it is extremely
high or to a normal pressure of ≤20 cm of CSF). If per-
sistent pressure elevation of ≥25 cm of CSF exists and
symptoms, repeat lumbar puncture daily until the CSF
pressure and symptoms have been stabilised for 1 to
2 days.
Brain imaging should be considered before lumbar
puncture in patients with focal neurologic signs or pro-
found coma, although its sensitivity for predicting cere-
bral herniation is poor [4].
Appendix 4 Antifungal treatment
All patients will receive amphotericin B deoxycholate
1 mg/kg/day for 2 weeks combined with fluconazole,
800 mg/day, for the first 2 weeks after randomisation.
This will be followed by 800 mg fluconazole per day for
8 weeks. After this point, patients are switched to flu-
conazole, 200 mg/day, secondary prophylaxis. This con-
tinues until the patient has had sustained immune
reconstitution (CD4 count >100 cells/μl) secondary to
antiretroviral therapy. This is consistent with current
IDSA and WHO guidelines for the treatment of crypto-
coccal meningitis.*
*Perfect JR, et al: Clinical Practice Guidelines for the
Management of Cryptococcal Disease. Clin Infect Dis 2010,
50:291–322., and Rapid Advice: Diagnosis, Prevention
and Management of Cryptococcal disease in HIV-
infected Adults, Adolescents and Children: World
Health Organization; 2011
Appendix 5 Amphotericin administration and
complications
Administration
Renal impairment occurs in 80% of patients receiving
amphotericin, and is reversible provided the total dose
does not exceed 4 g. Evidence suggests that sodium de-
pletion increases the chance of amphotericin-induced
nephrotoxicity. Administration of normal saline before
amphotericin infusion reduces this risk. This must be
followed by a dextrose flush, because amphotericin is in-
compatible with normal saline.
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1. Flush line with 50 to 100 ml dextrose 5%.
2. Administer 1,000 ml normal saline containing
20 mmol potassium chloride over a 2- to 4-hour
period (contraindications: fluid overload, cirrhosis,
heart failure)
3. Flush line with 50 to 100 ml dextrose 5%
4. Administer amphotericin
Dose: 1 mg/kg/day
Infusion solution: 5% dextrose
Rate of infusion: 4 hours
Management of amphotericin-induced renal impairment
1. Frequent monitoring in all patients of electrolytes,
creatinine and urea.
2. There is no need to reduce the dose of
amphotericin unless the creatinine is >3 times
upper limit of normal (ULN).
3. If creatinine exceeds 3 times ULN, discontinue
amphotericin for 1 day, then reintroduce at half the
previous dose, and gradually increase this dose to
the target level over the next 2 to 3 days, carefully
observing renal function.
Management of amphotericin-induced hypokalaemia
Reversible hypokalaemia is common in amphotericin
treatment. Potassium levels should be checked twice
weekly during the period of amphotericin administration.
Hypokalaemia can be treated with oral potassium chloride
(1 to 2 tablets 2 to 3 times daily according to response).
There is evidence that this can be helped by administering
a small daily dose of amiloride (10 mg) orally.
Management of rigors
A minority of patients may develop rigors and fevers
when starting their infusions with amphotericin. This
symptom usually resolves after a few days, but can be
helped by prophylactic chlorphentiramine or aspirin.
Anaphylaxis is rare with amphotericin, occurring in
less than 1% of patients.
References
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Appendix 6 Common terminology criteria for
adverse events
Hard copies of the CTCAE will be provided for the
study staff. Details of the CTCAE criteria can be found
at: http://ctep.cancer.gov/protocolDevelopment/electro-
nic_applications/ctc.htm.
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